New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 15, 2014
13:35 EDTLXRXLexicon study shows LX4211 lessens postprandial glucose levels
Lexicon Pharmaceuticals presented data at the 74th Scientific Sessions of the American Diabetes Association, ADA, in San Francisco on LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2, SGLT1 and SGLT2, that is designed to lower blood glucose levels through two insulin-independent mechanisms of action. Results presented from a clinical study showed that LX4211 significantly reduced postprandial glucose levels in type 2 diabetes patients with moderate to severe renal impairment.
News For LXRX From The Last 14 Days
Check below for free stories on LXRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 12, 2014
09:14 EDTLXRXOn The Fly: Pre-market Movers
Subscribe for More Information
September 11, 2014
18:35 EDTLXRXOn The Fly: After Hours Movers
Subscribe for More Information
16:33 EDTLXRXLexicon publication of Phase 2b study shows LX4211 provides meaningful benefit
Subscribe for More Information
September 10, 2014
11:06 EDTLXRXLexicon management to meet with Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use